Webinar

Antibody Discovery in 2025: How Industry Leaders are Adapting to Market Trends, Technological Innovations, and Economic Pressures

Join industry leaders from Twist Bioscience and Genovac for a dynamic roundtable discussion on the latest trends, technological innovations, and strategic adaptations shaping the future of antibody discovery in 2025.

Register now to gain expert insights into the future of antibody discovery and learn how industry leaders are adapting to these challenges!

Date: April 16, 2025
Time: 8 AM - 9 AM PST | 11 AM - 12 PM EST

First Name*

Last Name*

Email*

Company Name*

Job Title

Country*

Application Area*

Research Area*

Industry*

Product of Interest*

By submitting this form, I confirm that I would like to receive information from Bruker Cellular Analysis and I agree to the Website Privacy Policy and Terms of Conditions.*

PUSHING THE BOUNDARIES IN ABD | ROUNDTABLE

Antibody Discovery in 2025: How Industry Leaders are Adapting to Market Trends, Technological Innovations, and Economic Pressures

Overview

The antibody discovery landscape is evolving rapidly, driven by technological breakthroughs, shifting market trends, and economic pressures that challenge traditional workflows. From AI-driven lead optimization and automation to transgenic models and cell-free expression systems, the industry is transforming how therapeutic antibodies are identified and developed.

Join industry leaders from Twist Bioscience and Genovac for an exclusive roundtable discussion on the most pressing trends in antibody discovery, the impact of financial constraints on R&D strategies, and the cutting-edge innovations shaping the future of antibody therapeutics. Learn how companies are adapting to industry shifts, streamlining operations, and maximizing efficiency while driving scientific advancements.

Speakers

Colby Souders, Ph.D.

CSO, Twist Biopharma Solutions

Colby Souders earned his PhD in Cell and Molecular Biology from Texas A&M and previously held positions at Abveris, MassBiologics and Kanyos Bio (now Anokion). At MassBiologics, he worked to advance monoclonal antibodies for the prevention, treatment or diagnosis of various infectious and endogenous diseases, as well as develop related platform technologies to advance and expand the MassBiologics pipeline. Later, he joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. Colby joined Abveris in 2018 as the Chief Scientific Officer to establish best-in-class antibody discovery workflows and build a premium discovery engine with industry-leading timelines. He continues to hold his role as CSO of Twist Biopharma Solutions after Abveris was acquired by Twist Bioscience in 2021.

Brian Walters

CEO, Genovac

Brian Walters Brian Walters assumed the role of President & CEO of Genovac Antibody Discovery after leading a management-led buyout of Aldevron’s Antibody Discovery Business Unit. Most recently, Brian was serving as President of Aldevron’s Antibody Discovery Business Unit before leading the establishment of Genovac. Brian graduated from the University of Southern Mississippi with a Master of Science in Economic Development and received a Bachelor of Science from the University of North Dakota in Geography and Mathematics.

Vincent Pai

Director of Product Management, Bruker Cellular Analysis

Vincent Pai is Director of Product Management at Bruker Cellular Analysis. He has over 10 years of expertise in cell biology, nanotechnology, and microfluidics, with research experience from UC San Diego and Massachusetts General Hospital in Boston. He joined Berkeley Lights in 2016 and transitioned through roles as an applications engineer, program manager, and product manager. Following Bruker’s acquisition, Vincent now leads new product development for antibody discovery on the Beacon® optofluidic system.

In Partnership With

Live Webcast Details

Key Takeaways

Industry Trends & Economic Pressures: Gain insights into how leading companies are navigating financial challenges and adapting strategies to optimize discovery pipelines.
Cutting-Edge Technologies & AI: Explore how automation, AI-driven lead optimization, and transgenic models are transforming therapeutic development.
The Future of Antibody Discovery: Learn how the Beacon^® optofluidic system and other emerging technologies are shaping the next generation of antibody therapeutics.

Back to the Top